Cambrex buys stake in Zenara Pharma; NuPathe files NDA;

 @FierceBiotech: Waksal inks pair of hepatitis C pacts for his start-up. Article | Follow @FierceBiotech

 @JohnCFierce: I got my briefing book on BIO panels for 2011. It's boiled down to about 600 pgs. Good thing I have so many idle hours to fill. | Follow @JohnCFierce

Special Report: Notorious Names in Biopharma. Slideshow

Special Report: 10 Healthcare Bloggers We're Thankful For. Article

> Cambrex has purchased a 51 percent stake in Zenara Pharma, a Hyderabad, India-based that creates final dosage form products. Cambrex release

> NuPathe has filed an NDA for transdermal delivery of migraine meds. Report

> Energesis Pharmaceuticals plans to tap "good fat" in fighting obesity and diabetes, according to Xconomy. Report 

> Measuring three biomarkers from a single blood sample may help doctors identify patients who are at high risk of developing chronic kidney disease, according to data from a 2,345-patient study published in the Journal of the American Society of Nephrology. Report

> Nanoshells--hollow silica spheres covered with gold--were invented and are being tested in Houston. And they continue to surprise researchers with how effective they are. Researchers say they are killing breast cancer cells at a previously unreachable root level. Article

> No, HIFU is not a three-line poem. It's an acronym for High Intensity Focused Ultrasound, and the French ultrasound company EDAP TMS has announced that after three years of testing, it has proven that HIFU can direct ultrasound-sensitive liposomes to deliver cancer drugs. News

And Finally... Experts spar over the need for gene patents. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.